Provided by Tiger Trade Technology Pte. Ltd.

InspireMD

0.9202
+0.05035.78%
Volume:49.94K
Turnover:44.89K
Market Cap:42.78M
PE:-1.42
High:0.9490
Open:0.8500
Low:0.8500
Close:0.8699
52wk High:2.57
52wk Low:0.6300
Shares:46.49M
Float Shares:25.94M
Volume Ratio:0.59
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6464
EPS(LYR):-0.7584
ROE:-202.81%
ROA:-85.85%
PB:1.36
PE(LYR):-1.21

Loading ...

InspireMD Inc Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Jul 31

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

THOMSON REUTERS
·
Jul 31

InspireMD Eliminates Chief Commercial Officer Position

TIPRANKS
·
Jul 30

InspireMD Eliminates Chief Commercial Officer Role; Shane Gleason to Depart July 31

Reuters
·
Jul 30

InspireMD Receives Nasdaq Notice on Bid Price Compliance

TIPRANKS
·
Jul 24

Inspiremd Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule

Reuters
·
Jul 24

Inspiremd Director Raymond Cohen Resigns from Board, Effective July 1

Reuters
·
Jul 03

InspireMD grants 91,161 restricted shares to six new employees under inducement plan

Reuters
·
Jun 13

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 13

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 13

InspireMD says FDA reviews PMA supplement for CGuard Prime 80 cm stent in TCAR use

Reuters
·
Jun 11

InspireMD reports zero major adverse events at 30 days in CGUARDIANS II TCAR study of CGuard Prime 80 cm stent

Reuters
·
Jun 11

InspireMD - No Deaths, Strokes, or Myocardial Infarctions Reported Within 30 Days in Cguardians Ii

THOMSON REUTERS
·
Jun 11

InspireMD - Cguardians Ii Trial Achieves 100% Acute Device Success Rate

THOMSON REUTERS
·
Jun 11

InspireMD Inc: Anticipates Potential Approval of Cguard Prime 80 Cm Stent Implant in Second Half of This Year

THOMSON REUTERS
·
Jun 11

InspireMD Announces 30-Day Results From the Cguardians Ii Clinical Trial of the Cguard Prime 80 Cm Implant for Use in Tcar Procedures

THOMSON REUTERS
·
Jun 11

InspireMD Announces First Patient Enrolled in the Cguardians Iii Pivotal Study of the Switchguard Neuro Protection System for Use in Tcar Procedures

THOMSON REUTERS
·
Jun 08

InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures

GlobeNewswire
·
Jun 08

InspireMD Shareholders Approve Stock Increase and Board Slate

TIPRANKS
·
Jun 04

InspireMD shareholders approve increase in authorized common shares to 250 million

Reuters
·
Jun 04